MAP2K7 and melanoma: Correspondingly, Gebreyohannes et al. tested avapritinib, a highly selective inhibitor of KIT, on GIST PDX models with different KIT mutations, which had a superior or equal therapeutic effect compared to standard TKI.193 Combining BRAF and MEK inhibitors has been an effective strategy for BRAF-mutant melanoma, and mTOR signaling is a pathway suppressed under this treatment.